Microglia are emerging as critical regulators of neuronal function and behavior in nearly
every area of neuroscience. Initial reports focused on classical immune functions of …

Major depressive disorder (MDD) was previously hypothesized to be a disease of
monoamine deficiency in which low levels of monoamines in the synaptic cleft were …

Almost 70% of patients with mental disorders report sleep difficulties and 30% fulfill the
criteria for insomnia disorder. Cognitive behavioral therapy for insomnia (CBT-I) is the first …

Classic psychedelics, such as LSD, psilocybin, and the DMT-containing beverage
ayahuasca, show some potential to treat depression, anxiety, and addiction. Importantly …

The emerging therapeutic efficacy of ketamine and classical psychedelics for depression
has inspired tremendous interest in the underlying neurobiological mechanisms. We review …

Deep brain regions such as hippocampus, insula, and amygdala are involved in
neuropsychiatric disorders, including chronic insomnia and depression. Our recent reports …

Major depressive disorder represents a serious public health challenge worldwide;
however, the underlying cellular and molecular mechanisms are mostly unknown. Here, we …

The prefrontal cortex (PFC) serves as the chief executive officer of the brain, controlling the
highest level cognitive and emotional processes. Its local circuits among glutamatergic …

Major depressive disorder (MDD) is a prevalent psychiatric disease that involves
malfunctions of different cell types in the brain. Accumulating studies started to reveal that …

Hallucinations limit widespread therapeutic use of psychedelics as rapidly acting
antidepressants. Here we profiled the non-hallucinogenic lysergic acid diethylamide (LSD) …